Treatment for Multiple Myeloma

University of Illinois Cancer Center, Chicago, IL
Multiple Myeloma
All Sexes

Study Summary

This trial is testing whether it's safe to stop maintenance therapy for multiple myeloma patients who have had a stem cell transplant and are in remission.

Eligible Conditions
  • Multiple Myeloma

Treatment Effectiveness

Phase-Based Effectiveness

1 of 3
Phase 1

Similar Trials

Study Objectives

0 Primary · 6 Secondary · Reporting Duration: 3 years

Year 1
Number of participants that relapse per IMWG at 1 year after stopping maintenance therapy
Year 2
Number of participants that have a sustained MRD-negative VGPR or CR measured by a bone marrow biopsy
Number of participants that relapse per IMWG at 2 years after stopping maintenance therapy
3 months
Compare health-related quality of life (HRQoL) between MM patients stopping versus continuing maintenance therapy
3 years
Cell Count
Multiple Myeloma

Trial Safety

Phase-Based Safety

1 of 3

Similar Trials

Awards & Highlights

No Placebo Group
All patients enrolled in this trial will receive the new treatment.

Trial Design

0 Treatment Group

50 Total Participants · 0 Treatment Group

Primary Treatment: Treatment · No Placebo Group · Phase 1

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 3 years

Who is running the clinical trial?

University of Illinois at ChicagoLead Sponsor
558 Previous Clinical Trials
1,553,990 Total Patients Enrolled
4 Trials studying Multiple Myeloma
165 Patients Enrolled for Multiple Myeloma
Karen Sweiss, PhamDPrincipal InvestigatorUniversity of Illinois at Chicago

Eligibility Criteria

Age 18+ · All Participants · 1 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
Maintenance therapy refers to any treatment given after ASCT to prevent the return of myeloma and extend the period of being free from the disease. This includes drugs like lenalidomide, bortezomib, and RVD.

Frequently Asked Questions

Has this treatment earned the stamp of approval from the FDA?

"Our team at Power cautiously rated the safety of this treatment as a 1 because it is currently in Phase 1 trials, which implies there are limited findings to support its efficacy and safety." - Anonymous Online Contributor

Unverified Answer

Are there vacancies for participants in this scientific research endeavor?

"According to the database, recruitment for this medical trial is still ongoing. This research was initially posted on December 31st 2021 and recently updated on October 3rd 2022." - Anonymous Online Contributor

Unverified Answer

What is the sample size of individuals being observed in this clinical experiment?

"Affirmative. Data hosted on verifies that this medical experiment, which was first advertised on December 31st 2021, is currently recruiting participants. Approximately 50 patients must be enrolled from a single site." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.